NABIQASIM GROUP

w w w.n a b i q a si m .co m
THE GROUP
Nabiqasim Industries Pvt. Ltd.
Surge Laboratories Pvt. Ltd.
The Eastern Trade &
Distribution Co. (Pvt) Ltd
KEY MANAGEMENT
Leading Pharmaceutical manufac-
turing company offering wide
range of high quality branded
generics in almost all therapeutic
categories in domestic and inter-
national markets
Specialized Pharmaceutical Manu-
facturing Company with diverse
offering of Microencapsulated
APIs & branded generics in Paren-
teral dosage forms
Marketing & Distribution company
/exclusive representative of blood
derivative products of European
and North American companies in
Pakistan
Finance & Operational Planning
Muhammad Ali Majid is a visionary business leader who
during the last couple of decades has phenomenally
spearheaded Nabiqasim group. His positive attitude &
aggressive strategies built on cutting edge technology,
integrity, immaculate business acumen, and an unwavering
commitment to excellence inspired all the stakeholders and
transformed a customary pharmaceutical manufacturer into a
leading hi-tech, trendsetter pharmaceutical conglomerate of
the country. Under his management the Groups business
Muhammad Ali Majid exponentially expanded across the globe and revenues have
grown by manifolds.
Cheif Executive
He is among the most respected and admired pharmaceutical entrepreneur in the country
and felicitated on numerous occasions by the Pharma industry & PPMA (Pakistan Pharma-
ceutical Manufacturers Association).
Jalal Uddin Zafar is among the key members of Nabiqasim
Group and has been associated with the group for the last 13
years. His attributes include strong relationship management,
passionate business development acumen, and highly
effective domestic & international network with pharmaceuti-
cal manufacturers, suppliers, distributors, traders, franchis-
ers, regulators and other consultants. During the past decade
he has proven his ability to successfully launch new sales &
marketing projects, overseas business, drive business
expansion through aggressive sales initiatives, in sourcing &
Jalal Uddin Zafar licensing out projects that deliver market penetration,
synergetic advantages, market share, and revenue growth.
Senior General Manager
Business Development
Syed Zohair Irfan has been associated with the group for
more than a decade and has headed Finance, Supply Chain
& operational planning functions. He has vast experience in
executing strategic plans to the operational level & measures
outcomes against expectations thereon. He heads multi-func-
tion finance department, which facilitate commercially
focused decision-making at all levels of the organization. He
possesses extensive knowledge for cross-functional ERP
systems, operations and project management. He has
consistently demonstrated his abilities to increase competi-
tiveness, profitability and organizational effectiveness.
Syed Zohair Irfan
General Manager
 HISTORY
1947 - 66
One of the oldest Pharma business in the
country operations commenced even
before Pakistans independence.
Nabiqasim started as importer and distributor
of drugs, medicines, surgical supplies from
Europe, USA and Japan
1967- 1999
Nabiqasim was among the first few nation-
al companies to establish a small manufac-
turing unit.
Pharmaceutical Manufacturing was introduced
in 1960s in Pakistan. Nabiqasim started manu-
facturing of pharmaceutical products in 1967 at
Karachi and thereafter added cGMP compliant
sections of :
Tablets | Capsules | Syrups | Sachet | Creams |
Enema | Eye Drops | Vaginal Pessaries | Prosta-
glandins | Cephalosporins
2000 - 2004
Nabiqasim focused on exports through
aggressive collaborations with overseas
distributors and importers across Africa &
Asia.
The Group after gaining significant market share of
the local market started its exports to Asian and
African countries and since then has been gaining
market share of various export markets through
strategic collaborations with distributors & import-
ers.
Various quality management systems (QMS) certifi-
cations were acquired from international bodies.
New Facility (Surge) was established near Lahore
in 2000 for cephalosporins and liquid injectables.
2005 - 2014
Nabiqasim Introduced various latest manu-
facturing technologies in Pakistan.
The Group Introduced microencapsulation of
APIs through German technology as well as
successfully started Lyophlization operations &
regularly updated its facilities for cGMP compli-
ance.
Accredited by renowned certification Body
Bureau Veritas (France) for QMS (IMS)
and various international regulatory authori-
ties for GMP.
The Group has cGMP compliant facilities and
has been accredited for IMS (Integrated Man-
agement Systems) including ISO9001:2008,
ISO 14001 and OHSAS 18000.
The Group started its export to Russia, CIS,
Fareast, Francophone Africa & South
America enabling its access from semi reg-
ulated to regulated markets.
The Group besides its own branded generics
also collaborated with leading distributors and
franchisers of overseas markets and offered
contract manufacturing services for their
brands. The synergized effect was phenomenal
.
GROUP OVERVIEW
Presence in
The group has 18 marketing teams comprising of around 1250 marketing professionals who are
promoting the branded generics to more than 55000 doctors, medical practitioners, opinion Therapeutic Segment
leaders & consultants.

Nabiqasim groups products are always in high demand and available at more than 60,000
pharmacies as well as available at all leading hospitals, Institutions, community health centers &
Clinics in the country.

The group is one of the major supplier to public and private tenders floated by various authorities,
institutions, armed forces, federal and provincial governments and enjoys high repute due to
premium quality.

Nabiqasim group has succesfully collaborated with international pharmaceutical companies for
numerous projects including marketing and promotion of biological & other unique products in
Pakistan which are not being manufactured in the country.

The Nabiqasim group has a dedicated team of highly skilled, trained and experienced regulatory
professionals who are continously preparing the registration dosiers and other regulatory docu-
ments to the domestic and international drug regulatory authority. The group has more than 650
product registrations of branded generics in domestic and international markets.

During the last couple of decade the group has introduced various unique products (branded Focused Markets
generics) in local and international markets and extended its outreach to more than 45 countries
including Central Asia, Asia, Russia, Fareast, Francophone & West Africa, East Africa & Southern Afghanistan Gabon Mozambique Nigeria
Azerbaijan Georgia Myanmar Tajikistan
Africa. Argentina Ghana Philippine Tanzania
Algeria Indonesia Peru Togo
Nabiqasim group has also opened its overseas offices in Uzbekistan & Tajikistan. Furthermore, Bangladesh Iran Russia Turkmenistan
the company now is in the process of opening commercial / representative offices in its various Belarus Jordan Rwanda Turkey
Benin Kazakhstan Senegal Tunisia
focused export terrotories to explore the true potentials thereon. Brazil Kenya Saudi Arabia Yemen
Cambodia Kuwait Sierra Leone UAE
Nabiqasim Industries also has plans to setup an overseas manufacturing facility to explore the Cameroon Kyrgyzstan Somalia Uganda
true potentials and opportunities prevailing in the semi regulated to regulated markets of MENA, Chad Lebanon Sri-Lanka Ukraine
China Malaysia Singapore Uzbekistan
South & Central America, Eastern Europe & Baltic Regions, EU & UK. Columbia Mali South Korea Vietnam
Ecuador Mauritania Sudan Yemen Zambia
Egypt Mauritius Switzerland
France Mexico Ivory Coast
 PRODUCTION FACILITIES
Nabqasim Group has two cGMP compliant manufacturing
sites in Karachi & Sheikhupura (Near Lahore) which are
well equipped with latest machinery and equipments.

QUALITY ACCREDITATION

ISO 9001
ISO 9001:2008 | ISO 14001 | OHSAS-18000

INTERNATIONAL APPROVALS
The facilities have been approved by various drug regu-
latory authoritories of different countries including Ivory
Coast, Uganda,Kazakhstan, Yemen, Kenya, Tanzania,
Sudan etc. Tablets Syrup Enema
STRATEGIC COLLABORATIONS / CUSTOMERS

Creams & Ointments Microencapsulated API Sachet

Lyophilized Injections Cephlosporin Liquid Injectables

 STRATEGIC PRODUCTS PORTFOLIO
Kleen Enema 4000K

Kleen Enema is a unique multi-purpose branded generic which is mainly 3500K

used for relief of constipation, Bowel Cleaning before rectal examination,

3000K

2500K
abdominal X-rays, Pelvic and Abdominal Surgery, Child Birth, etc.

Units
2000K

Dosage Form 1500K

Laxative Disposable Enema Liquid (135 ml)

1000K

500K

Recommended in 0K
2010 2011 2012 2013 2014

Preparation for delivery, Bed ridden patient, Postoperative cases, Prepar-

ing the patient for surgery, Preparing the colon for X-Ray, Endoscopy,
Sigmoidoscopic examination, Postpartum cases.

Current Export Markets :

Russia Uzbekistan Kenya Azerbaijan Tajikistan Kazakhstan Uganda

Turkmenistan Kyrgyzstan Afghanistan Sri-lanka Yemen Zamia

Potential Export Regions :

Eastern Europe, EU, MENA, South America
STRATEGIC PRODUCTS PORTFOLIO
Glandin-E2
Glandin E-2 is a branded generic of Dinoprostone-E2 (Hormonal product)
350K

primarily used for induction of labour and considered as the safest generic/
300K

molecule to facilitate child birth. The product due to its unique nature and 250K

special manufacturing and cold chain requirements is manufactured by only 200K

few companies in the world. 150K

Dosage Form 100K

Vaginal Tablets & Gels

50K

0K
2010 2011 2012 2013 2014

Benefits
Induction of labour in viable pregnancies is mainly performed with prosta-
glandin PG E2 derivates as it softens the cervix by altering the extracellular
collagen matrix, enhances dilatation by relaxing cervical smooth muscle and
causes uterine contraction.
Current Export Markets :

Srilanka Uzbekistan Myanmar Malaysia

Tanzania Zambia Kenya Uganda

STRATEGIC PRODUCTS PORTFOLIO
Lyophilized Product Range
Lyophilization technology was adopted to increase the stability of certain mol-
350K

ecules that were unstable in injectable solution form. The process includes
300K

following three major steps : 250K

200K

1. Freezing to convert most of the solution into ice. 150K

2. Primary drying to sublime the ice. 100K

3. Secondary drying to remove unfrozen water by desorption.

50K

Advantages of Lyophilization 0K
2010 2011 2012 2013 2014

Omeprazole Infusion
Es-omeprazole Infusion
Pantoprazole Infusion
Vancomycin Infusion
Clarithromycin Infusion

Branded Generic Lyophilized Product Range

Omeprazole Infusion
Es-omeprazole Infusion
Pantoprazole Infusion
Vancomycin Infusion
Clarithromycin Infusion
STRATEGIC PRODUCTS PORTFOLIO
Microencapsulated APIs Range
Nabiqasim Group introduced the microencapsulation technology based
on latest German equipments in Pakistan and is successfully manufactur-
ing various microencapsulated APIs & Excipients at all levels (Develop-
ment, Commercial and Bulk Production).
Benefits of Microencapsulation of APIs
Highly Effective & Stable Taste Masking of Bitter Molecules,
Formulation of APIs into High Quality Enteric Coated Pellets
Coating of APIs for Controlled & Targeted Drug Release/ Delivery
Moisture Protective Coating for Moisture Sensitive Materials
Coating of Granules which can be used for the Orally Dispersible Tablets

Flagship Microencapsulated APIs

Clarithromycin Taste Masked Granules Dry Suspension / Dry Syrup/ Sachet
Azithromycin Taste Masked Granules Dry Suspension / Dry Syrup/ Sachet
Ciprofloxacin Taste Masked Granules Dry Suspension / Dry Syrup/ Sachet
Paracetamol Taste Masked Granules Orally Dispersible Tablets
Aspirin Enteric Coated Granules Combination Tablets
Es-Omeprazole Enteric Coated Pellets Capsules
Duloxetine HCl Delayed Release Pellets Capsules

350K

300K

250K

200K

150K

100K

50K

0K
2010 2011 2012 2013 2014
SYNOPSIS

67 years of operating history and invaluable experience in

pharmaceutical sector with outstanding track record

3rd largest exporter of pharma products in Pakistan catering

to demand from 40 countries across the globe with overseas
rep offices & distribution network

5th largest market share in the country with diverse portfolio of

pharma products

Pioneers of manufacturing Unique Branded Generics and

Microencapsulated APIs in Pakistan

More than 500 branded generics registrations in domestic

and international markets
Thank You